| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net Loss | ||||||
-3,888 | -10,849 | -7,366 | -3,303 | -9,311 | - | -1,526 |
Net loss for the period | ||||||
- | - | - | - | - | -3,127 | - |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Loss on sale of securities | ||||||
3 | -15 | - | - | - | - | - |
Accrued (income)/loss on marketable securities | ||||||
-3 | 11 | 1 | -14 | -4 | - | - |
Depreciation and amortization | ||||||
74 | 234 | 249 | 286 | 299 | 349 | 354 |
Loss on Disposal of Property and Equipment | ||||||
9 | 156 | - | - | - | - | - |
Impairment of intangible assets | ||||||
32 | 716 | - | - | - | - | - |
Impairment of Other Assets | ||||||
- | 64 | - | - | - | - | - |
Reserve for obsolete inventory | ||||||
371 | 279 | - | - | - | - | - |
Reserve and write-off for obsolete inventory | ||||||
- | - | - | 32 | - | - | - |
Reserve for obsolete inventory | ||||||
- | - | 1,208 | - | 0 | - | - |
Accrued interest and dividends on marketable securities | ||||||
- | - | - | - | - | 18 | 0 |
Decrease in reserve for inventory obsolescence | ||||||
- | - | - | - | - | -3 | 0 |
Reserve for doubtful trade receivables | ||||||
5 | 156 | 450 | - | - | - | - |
Reserve for doubtful other receivables | ||||||
100 | - | - | - | - | - | - |
Impairment of non-current assets | ||||||
- | - | - | - | 466 | 0 | - |
Allowance for doubtful accounts | ||||||
- | - | - | - | -2,163 | 0 | - |
Expenses related to modification of warrants | ||||||
- | - | 764 | 0 | - | - | - |
Gain from other non-operating activities | ||||||
- | - | - | - | 6 | 4 | - |
Allowance for/(reversal of) doubtful accounts | ||||||
- | - | - | -1,153 | - | - | - |
Amortization of deferred compensation | ||||||
- | 3 | 21 | 30 | - | - | - |
Stock-based compensation to employees - options | ||||||
- | 6 | 17 | 27 | 23 | - | 0 |
Share based compensation to an employee - common stock | ||||||
27 | 27 | 95 | - | - | - | - |
Share based compensation to directors - restricted stock units | ||||||
362 | - | - | - | - | - | - |
Fair value of restricted common stock issued for services | ||||||
- | - | - | - | 344 | - | - |
Gain from demutualization of insurer | ||||||
- | - | - | - | - | - | 91 |
Gain on sale of equity investment | ||||||
- | - | - | - | - | - | 99 |
Share based compensation - shares issued to vendors | ||||||
10 | 12 | - | - | - | - | 0 |
Share based compensation to officers | ||||||
- | - | 163 | - | - | - | - |
Share based compensation to an employees - restricted stock | ||||||
- | - | - | 0 | - | - | - |
Share based compensation to officers - restricted stock | ||||||
- | - | - | 0 | - | - | - |
Share based compensation to non-employees - options | ||||||
- | - | 2 | 23 | 28 | - | - |
Share based compensation to non-employees | ||||||
- | - | 5 | - | - | - | - |
Share based compensation to non-employees - restricted stock | ||||||
- | - | - | 0 | - | - | - |
Non-cash share based compensation - options | ||||||
- | - | - | - | - | -549 | - |
Non-cash share based payments for services - shares issued | ||||||
- | - | - | - | - | -196 | - |
Reversal of old trade payables | ||||||
- | - | - | - | - | - | 91 |
Change in assets and liabilities | ||||||
Increase in trade receivables | ||||||
-128 | -631 | 781 | 138 | -513 | 1,899 | 17 |
Decrease in trade receivables - related party | ||||||
- | - | - | 0 | 0 | - | 1,199 |
Decrease in notes receivables - related party | ||||||
- | - | - | - | -176 | 266 | 0 |
Decrease in deposits and other receivables | ||||||
-9 | -7 | -7 | -71 | 54 | 37 | -0 |
Decrease in license fees receivable - related party | ||||||
- | - | - | - | - | - | -450 |
(Increase)/Decrease in inventories | ||||||
-14 | -83 | -119 | 187 | 226 | -123 | 37 |
Decrease in prepaid expenses | ||||||
-103 | 225 | -123 | -17 | 76 | - | - |
Decrease in prepaid expenses - related party | ||||||
- | - | - | -76 | - | - | - |
Decrease in prepaid expenses - related party | ||||||
- | - | - | - | 0 | - | - |
Decrease in other assets | ||||||
-9 | - | 9 | 0 | - | -56 | 95 |
Increase in trade and other payables | ||||||
-443 | 188 | 87 | -205 | 827 | 538 | 116 |
Increase/(decrease) in trade and other payables - related party | ||||||
- | - | - | 234 | 0 | -6 | -51 |
Decrease in legal settlement liabilities | ||||||
- | - | - | - | - | - | -106 |
Increase in deferred revenue | ||||||
- | - | - | - | -305 | -333 | -333 |
Net cash used by operating activities | ||||||
-3,074 | -8,502 | -5,080 | -4,173 | - | - | - |
Net cash used in operating activities | ||||||
- | - | - | - | -5,132 | -3,883 | -2,730 |
Cash flows from investing activities: | ||||||
Purchases of property, plant and equipment | ||||||
- | 68 | 54 | 123 | 112 | 24 | 123 |
Proceeds from the sale of equipment | ||||||
6 | - | - | - | - | - | - |
Short-term note receivable | ||||||
100 | - | - | - | - | - | - |
Purchases of marketable securities | ||||||
6,704 | 6,604 | 7,709 | 35 | 60 | 12,551 | 0 |
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture | ||||||
- | - | - | - | 64 | 0 | - |
Proceeds from other non-operating activities | ||||||
- | - | - | - | 6 | - | - |
Proceeds from demutualization of insurance carrier | ||||||
- | - | - | - | - | 4 | 91 |
Proceeds from sale of equity investment | ||||||
- | - | - | - | - | - | 100 |
Proceeds from sale of marketable securities | ||||||
2,857 | 6,313 | 2,749 | 4,003 | 5,310 | 3,284 | 0 |
Net cash provided by investing activities | ||||||
-3,940 | -359 | -5,014 | 3,843 | - | - | - |
Net cash provided/(consumed) by investing activities | ||||||
- | - | - | - | 5,078 | -9,286 | 68 |
Cash flows from financing activities | ||||||
Proceeds from note receivable - related party for Series A Convertible Preferred Stock | ||||||
- | - | - | - | - | - | 225 |
Payment of short-term note payable - related party | ||||||
- | - | - | - | - | 307 | -307 |
Proceeds from other receivable for London Private Placement | ||||||
- | - | - | - | - | - | 0 |
Net proceeds from issuance of common stock | ||||||
2,147 | 1,950 | 5,803 | 0 | - | 745 | 1,599 |
Net proceeds from issuance of prepaid equity forward contracts for the purchase of common stock | ||||||
4,817 | - | 3,675 | 0 | - | - | - |
Net proceeds from the exercise of prepaid equity forward contracts for the purchase of common stock | ||||||
0 | - | - | - | - | - | - |
Net proceeds from exercise of warrants for common stock | ||||||
- | 7,155 | 981 | 0 | - | - | - |
Net cash provided by financing activities | ||||||
6,965 | 9,105 | 10,460 | 0 | - | - | - |
Net increase in cash and restricted cash | ||||||
-49 | 243 | 365 | - | - | - | - |
Net proceeds from issuance of common stock in initial public offering | ||||||
- | - | - | - | - | 13,101 | 0 |
Dividend distribution on Series A Convertible Preferred Stock | ||||||
- | - | - | - | - | 15 | 0 |
Net cash provided by financing activities | ||||||
- | - | - | - | - | 13,523 | 2,132 |
Net increase/(decrease) in cash | ||||||
- | - | - | -329 | -53 | 352 | -529 |
Supplemental cash flow information: | ||||||
Cash paid for: | ||||||
Income Taxes | ||||||
- | 2 | 1 | - | - | - | - |
Supplemental Schedule of Non-Cash Financing and Investing Activities | ||||||
Net unrealized gains/(losses) on marketable securities | ||||||
43 | -25 | - | - | - | - | - |
Conversion of Series B Preferred Stock to common shares | ||||||
- | 1,755 | - | - | - | - | - |
Issuance of restricted common stock grants to officers | ||||||
- | - | - | 54 | 0 | - | - |
Net unrealized gains on marketable securities | ||||||
- | - | - | 6 | - | - | - |
Net unrealized gains on marketable securities | ||||||
- | - | - | - | 13 | -20 | 0 |
Settlement of note receivable in the form of inventory | ||||||
- | - | - | 750 | 0 | - | - |
Settlement of note receivable in the form of prepaid expense | ||||||
- | - | - | 549 | - | - | - |
Settlement of note receivable in the form of prepaid expense | ||||||
- | - | - | - | 0 | - | - |
Conversion of trade receivable as of December 31, 2013 to a note receivable in the year ended December 31, 2014 | ||||||
- | - | - | - | - | 1,209 | 0 |
Issuance of restricted common share grants to directors and officers accrued in 2014 | ||||||
- | - | - | - | 697 | 0 | - |
Other receivable for proceeds of London Private Placement | ||||||
- | - | - | - | - | - | 745 |